Malaysia

Population 2015: 30 million

<table>
<thead>
<tr>
<th>Tuberculosis profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rate (per 100 000 population per year)</td>
</tr>
<tr>
<td>0</td>
</tr>
</tbody>
</table>

Mortality (excludes HIV+TB)

- **Rate (per 100 000 population)**
  - 2015: 2.4 (1.4–3.8)

Mortality (HIV+TB only)

- **Rate (per 100 000 population)**
  - 2015: 0.23 (0.059–0.52)

Incidence (includes HIV+TB)

- **Rate (per 100 000 population)**
  - 2015: 27 (23–31)

Incidence (HIV+TB only)

- **Rate (per 100 000 population)**
  - 2015: 1.5 (1.2–1.7)

Incidence (MDR/RR-TB)**

- **Rate (per 100 000 population)**
  - 2015: 0.53 (0.41–0.64)

Estimated TB incidence by age and sex (thousands)*, 2015

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Females</th>
<th>Males</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14 years</td>
<td>1.5 (0.97–2)</td>
<td>1.3 (0.9–1.7)</td>
<td>2.8 (2.1–3.4)</td>
</tr>
<tr>
<td>&gt; 14 years</td>
<td>8.7 (5.8–12)</td>
<td>16 (12–19)</td>
<td>24 (22–27)</td>
</tr>
<tr>
<td>Total</td>
<td>10 (6.8–14)</td>
<td>17 (13–21)</td>
<td>27 (23–31)</td>
</tr>
</tbody>
</table>

TB case notifications, 2015

- **Total cases notified**: 24 220
- **Total new and relapse**: 23 565
  - % tested with rapid diagnostics at time of diagnosis: 2%
  - % with known HIV status: 98%
  - % pulmonary: 87%
  - % bacteriologically confirmed among pulmonary: 75%

Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence)**, 2015: 87% (75–100)
- **TB patients facing catastrophic total costs**: 0.1 (0.06–0.15)
- **TB/HIV care in new and relapse TB patients**, 2015
  - Number (%)
    - Patients with known HIV-status who are HIV-positive: 1 157 (5%)
      - on antiretroviral therapy: 574 (50%)

Drug-resistant TB care, 2015

- **Estimated MDR/RR-TB cases among notified pulmonary TB cases**: 350 (270–430)
- **Estimated % of TB cases with MDR/RR-TB**: 1.5% (1.2–1.9) 3.1% (1.3–5.9)
- **% notified tested for rifampicin resistance**: 44% 54% 16 565
- **MDR/RR-TB cases tested for resistance to second-line drugs**: 98
- **Laboratory-confirmed cases**
- **Patients started on treatment ******: MDR/RR-TB: 85, XDR-TB: 0

Treatment success rate and cohort size

- **Success**: 78% 59% 52% 62% 62% 68%
- **Cohort**: 23 982 59% 83% 68% 1

TB preventive treatment, 2015

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 71%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

TB financing, 2016

- **National TB budget (US$ millions)**: 15
- **Funding source**: 100% domestic, international, 0% unfunded

---

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

Generated: 2017-04-09 Data: www.who.int/tb/data